10.1038/nature09691PubMed Abstract | CrossRef Full Text | Google Scholar 138 SrividyaN.LangeI.LangeB
The mitochondrial impairment in FM is evident from reduced bioenergetic health index (BHI) and increased mitochondrial miRNAs (mitomiR-145-5p) in peripheral blood mononuclear cells (PBMCs), which regulate oxidative stress responses ( Observational studies indeed suggest that oxidative stress disrupts neurotransmitter regulation, particularly serotonin ( Lipid metabolism alterations and fibromyalgia Recent metabolomic studies have highlighted significant alterations in lipid metabolism in FM patients, particularly shifts in phospholipid composition ( Notably, LPC (16:0), a lipid oxidation product, is elevated in FM and directly activates acid-sensing ion channel 3 (ASIC3) on nociceptors, leading to hyperalgesia in animal models ( Antioxidant defense impairment in fibromyalgia The imbalance between ROS production and antioxidant defenses is a feature of FM pathophysiology ( Several studies have shown that antioxidant enzyme deficiencies, including low SOD, glutathione peroxidase, and catalase, correlate inversely with disease severity measures such as the Fibromyalgia Impact Questionnaire (FIQR), pain scores, and anxiety levels ( Further, the nuclear factor erythroid 2-related factor 2 (NRF2) pathway is a master regulator of antioxidant and cytoprotective gene expression, crucial for cellular defense against oxidative stress
Before switching, a clinician would need to review: Which treatment you are currently taking Your current dose How long you have been taking it Your side effects Your weight loss progress Your medical history Your other medication Switching is not just a straight swap
Weighing yourself consistently, preferably at the same time each day, can help you observe any trends in weight reduction
Figure 2 presents the proportion of patients (X axis) whose percentage reduction from baseline in complex partial seizure rates was at least as great as that indicated on the Y axis in the monotherapy study
